Health
Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer – OncLive
Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast…
Chau T. Dang, MD, the Regional Care Network Medical Site Director at Memorial Sloan Kettering Westchester, discusses the safety profile of pertuzumab (Perjeta) plus trastuzumab (Herceptin) in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.
The 5-year results from the final analysis of the phase 2 BERENICE trial (NCT02132949), which were presented during the ESMO Breast Cancer Virtual Meeting 2021, showed that in cohort A of the study, in which patients…
-
Noosa News24 hours agoMeasles alert issued across popular south-east attractions
-
General24 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
Noosa News22 hours agoBrisbane’s covert cameras catching more than just litterbugs
-
Noosa News8 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites